Entrada Therapeutics Inc (TRDA)
13.52
+0.36
(+2.77%)
USD |
NASDAQ |
May 06, 16:00
14.00
+0.48
(+3.51%)
After-Hours: 18:45
Entrada Therapeutics Price to Book Value: 1.875 for May 6, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 1.824 |
| May 02, 2024 | 1.88 |
| May 01, 2024 | 1.837 |
| April 30, 2024 | 1.643 |
| April 29, 2024 | 1.711 |
| April 26, 2024 | 1.726 |
| April 25, 2024 | 1.714 |
| April 24, 2024 | 1.723 |
| April 23, 2024 | 1.787 |
| April 22, 2024 | 1.816 |
| April 19, 2024 | 1.684 |
| April 18, 2024 | 1.651 |
| April 17, 2024 | 1.694 |
| April 16, 2024 | 1.764 |
| April 15, 2024 | 1.787 |
| April 12, 2024 | 1.795 |
| April 11, 2024 | 1.838 |
| April 10, 2024 | 1.736 |
| April 09, 2024 | 1.841 |
| April 08, 2024 | 1.865 |
| April 05, 2024 | 1.915 |
| April 04, 2024 | 1.917 |
| April 03, 2024 | 1.915 |
| April 02, 2024 | 1.924 |
| April 01, 2024 | 1.908 |
| Date | Value |
|---|---|
| March 28, 2024 | 1.964 |
| March 27, 2024 | 1.990 |
| March 26, 2024 | 1.908 |
| March 25, 2024 | 1.855 |
| March 22, 2024 | 1.902 |
| March 21, 2024 | 1.877 |
| March 20, 2024 | 1.851 |
| March 19, 2024 | 1.761 |
| March 18, 2024 | 1.720 |
| March 15, 2024 | 1.772 |
| March 14, 2024 | 1.691 |
| March 13, 2024 | 1.762 |
| March 12, 2024 | 1.606 |
| March 11, 2024 | 1.630 |
| March 08, 2024 | 1.758 |
| March 07, 2024 | 1.744 |
| March 06, 2024 | 1.718 |
| March 05, 2024 | 1.694 |
| March 04, 2024 | 1.708 |
| March 01, 2024 | 1.894 |
| February 29, 2024 | 1.825 |
| February 28, 2024 | 1.792 |
| February 27, 2024 | 1.883 |
| February 26, 2024 | 1.907 |
| February 23, 2024 | 1.842 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
0.6208
Minimum
May 09 2022
3.069
Maximum
Oct 31 2022
1.824
Average
1.883
Median
Apr 25 2023
Price to Book Value Benchmarks
| GlycoMimetics Inc | 0.5268 |
| Lyell Immunopharma Inc | 0.9835 |
| Candel Therapeutics Inc | 20.47 |
| Eliem Therapeutics Inc | 2.203 |
| NovaBay Pharmaceuticals Inc | 2.017 |
Price to Book Value Related Metrics
| PS Ratio | 3.504 |
| Price to Free Cash Flow | 3.369 |
| Price | 13.52 |
| Earnings Yield | -1.92% |
| Market Cap | 454.45M |